Headache Clinic INI Grottaferrata, Rome, Italy.
J Headache Pain. 2010 Jun;11(3):259-65. doi: 10.1007/s10194-010-0194-3. Epub 2010 Feb 26.
Hemicrania continua (HC) and new daily-persistent headache (NDPH) represent the only two forms of chronic daily headache in Chap. IV "Other Primary Headaches" of the second edition of the International Classification of Headache Disorders. HC and NDPH are rare and poorly defined from a pathophysiological point of view; as a consequence, their management is largely empirical. Indeed, there is a lack of prospective, controlled trials in this field, and treatment effectiveness is basically inferred from the results of sparse open-label trials, retrospective case series, clinical experience and expert opinions. In this narrative review we have summarised the information collected from an extensive analysis of the literature on the treatment of HC and NDPH in order to provide the best available and up-to-date evidence for the management of these two rare forms of primary headache. Indomethacin is the mainstay of HC management. The reported effective dose of indomethacin ranges from 50 to 300 mg/day. Gabapentin 600-3,600 mg tid, topiramate 100 mg bid, and celecoxib 200-400 mg represent the most interesting alternative choices in the patients who do not tolerate indomethacin or who have contraindications to its use. NDPH is very difficult to treat and it responds poorly only to first-line options used for migraine or tension-type headache.
丛集性头痛（HC）和新的每日持续性头痛（NDPH）是第二章“其他原发性头痛”中慢性每日头痛的两种形式。HC 和 NDPH 从病理生理学角度来看是罕见且定义不明确的；因此，它们的治疗主要是经验性的。事实上，该领域缺乏前瞻性、对照试验，治疗效果基本上是从稀疏的开放标签试验、回顾性病例系列、临床经验和专家意见的结果推断出来的。在这篇叙述性综述中，我们总结了从对 HC 和 NDPH 治疗的文献广泛分析中收集到的信息，以便为这两种罕见原发性头痛的治疗提供最佳的现有和最新证据。吲哚美辛是 HC 管理的主要药物。报告的吲哚美辛有效剂量范围为 50 至 300 毫克/天。加巴喷丁 600-3600 毫克 tid、托吡酯 100 毫克 bid 和塞来昔布 200-400 毫克是不耐受吲哚美辛或有其使用禁忌的患者的最有趣的替代选择。NDPH 非常难以治疗，仅对用于偏头痛或紧张型头痛的一线药物有反应。
